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 The arabinose operon in Escherichia coli encodes the genes necessary to 
metabolize the sugar arabinose. AraC, the operon’s regulatory protein, induces 
transcription of the araBAD genes in the presence of arabinose, but repress transcription 
through DNA looping in the absence of arabinose. The operon serves as a model system 
for studying the regulation of gene expression at a molecular level. However, the 
structure and mechanisms of AraC remain incompletely characterized. AraC exists as a 
relatively rigid dimerization domain (DD) connected to two DNA-binding domains 
(DBDs) by flexible linkers. Crystallization of full-length AraC has been repeatedly 
unsuccessful, so new ways to observe structure must be considered. 
Here, I study the loop region between two α-helices within the DD to observe 
whether the loop may play a role in AraC’s response to arabinose. I also create and test a 
fluorescence-based assay to measure AraC function in vivo. Finally, I develop a genetic 
method to probe structural aspects of AraC through the identification of complementing 
mutations. 
Some single-amino acid substitutions can be corrected by a complementing 
substitution on a nearby residue. Using an AraC-encoding plasmid transformed into cells 
lacking AraC, loss-of-function mutations can be easily generated and isolated. These 
mutations can be reverted to generate araC genes possessing both the original loss-of-
function mutation and a second-site correcting mutation in a presumably proximal 
residue. With knowledge of the locations of complementing residues, it will be possible 
to identify intra- and inter-domain interactions in AraC and predict tertiary structure. 




improved models of protein folding, the synthesis of engineered peptides, and incisive 
methods for investigating mechanistically important domain-domain interactions. 
 Studies in the loop of AraC showed that introducing a cysteine into residues 144 
and 145 caused aggregation and a non-functional protein. However, randomization of 
loop residues generated mutants that were able to both induce and repress transcription, 
indicating that mutation in the loop without the loss of function is possible. Lastly, I used 
multiple approaches to optimize a genetic method of generating complementing 
mutations. The system I propose lays the groundwork for large-scale genetic screens to 







 I began working in the Schleif lab in May of 2014. At the time, I was a freshman 
in college who had not taken biochemistry, cell biology, or genetics. For the first year 
that I worked in the lab, I was admittedly conducting experiments whose principles I did 
not yet fully understand. Furthermore, the breadth of experiments used to study AraC 
meant that the moment I finally understood a concept, I was confronted with another 
alien one. A naïve person might say that research on a prokaryotic operon ought to be 
relatively straightforward – that at a time when science has progressed to CRISPR and in 
vivo gene editing, surely studying the best-characterized bacterial species should have 
few difficulties and surprises. 
 I quickly learned that this was not the case. In presenting us with AraC, Nature 
was kind enough to provide a protein that led to the discovery of DNA looping and 
demonstrated a system in which a single protein acts to actively induce and actively 
repress transcription. Unfortunately, Nature was not kind enough to make that protein 
easy to work with. I was often working more to make an experiment work than to 
actually obtain a result. The unexpected result that I did find, however, was how much I 
learned while diagnosing each problem. Although there were many experiments that did 
not have the outcome I had hoped for, no experiment was worthless. Even if it did not 
produce a finding of significance, every experiment still contributed to my growth as a 
scientist. As I turn to a new chapter of my life, medicine, I can say with confidence that 
the past four years have taught me to consider the intricate details of a biological system, 
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CHAPTER 1: INTRODUCTION 
The arabinose operon in Escherichia coli encodes the proteins necessary to 
metabolize L-arabinose, a five-carbon sugar. Acting together, eight genes in the operon 
allow the bacterium to import and catabolize the sugar, as well as regulate the levels of 
the associated proteins. Arabinose enters a cell through one of two methods: a low-
affinity, high-capacity transporter (AraE) or a high-affinity, low-capacity transport 
system (AraF, AraG, and AraH) (Khlebnikov, Risa, Skaug, Carrier, & Keasling, 2000). 
AraE is regulated by the PE promoter, while AraF, AraG, and AraH are regulated by a 
mutual PFGH promoter. After arabinose uptake, three enzymes (AraB, AraA, and AraD) 
metabolize intracellular arabinose into D-xylulose 5-phosphate, which then enters central 
metabolism pathways; all three enzymes are regulated by a mutual PBAD promoter (R. 
Schleif, 2003). Finally, the protein AraC – with the araC gene controlled by its own PC 
promoter – regulates the operon, functioning as both a transcriptional activator and 
repressor. When arabinose is present, AraC binds the sugar and induces transcription of 
the araB, araA, and araD (araBAD) genes by activating the PBAD promoter (Figure 1). In 
the absence of arabinose, AraC represses transcription. This dual activating-repressing 
ability of AraC is explained by the phenomenon of DNA looping, which results from the 
protein’s structure and its interaction with DNA (R. Schleif, 2010). 
AraC is a homodimer; each monomer is composed of a dimerization domain (DD) 
and a DNA-binding domain (DBD) connected by a six-residue linker. The DD portion of 
each monomer contains two α-helices connected by a short loop, a β-barrel that forms the 
arabinose-binding pocket, and an N-terminal arm (Soisson, MacDougall-Shackleton, 




regulate transcription. In the absence of arabinose, AraC forms a DNA loop by binding to 
two half-sites, which are segments of DNA named because each alone constitutes half of 
a complete AraC binding. Without arabinose, AraC binds to the araO2 and araI1 half-
sites. These sites are 210 DNA base-pairs apart, so the binding of AraC to both sites 
forces a looping conformation of the DNA (Lobell & Schleif, 1990). The loop prevents 
RNA polymerase from accessing both the PC and PBAD promoters. Thus, in the absence of 
arabinose, AraC represses its own transcription in addition to repressing transcription of 
the araBAD genes (Figure 1) (R. Schleif, 2003). However, when arabinose is present, it 
binds to AraC and changes the conformation of the protein, so AraC binds instead to two 
adjacent half-sites: araI1 and araI2 (Wu & Schleif, 2001b). In this setting, the DNA loop 
is not formed, and AraC forms a complex with cyclic AMP binding protein (CAP) and 







Figure 1. An overview of AraC-mediated regulation of transcription. In the absence of arabinose, AraC 
represses transcription by binding to the araO2 and araI1 half-sites, forming a DNA loop. In the presence of 
arabinose, AraC binds instead to the araI1 and araI2 half-sites, breaking the loop and inducing transcription. 
Arabinose is indicated as a red circle (R. Schleif, 2003). 
 
 The conformational change of AraC induced upon the binding of arabinose is not 
yet fully understood. Previous research has indicated that the N-terminal arms play a role 
in orienting the DBDs to bind half-sites. It has been thought that in the absence of 
arabinose, each arm adopts a structure on the DD upon which the DBDs bind, creating a 
rigid protein that cannot bind the adjacent araI1 and araI2 half-sites (R. Schleif, 2010). 




flexibility. As a result, AraC is able to bind to the adjacent half-sites (Rodgers, Holder, 
Dirla, & Schleif, 2009). The linkers connecting each DBD to the DD are thought to play 
a role in the conformational change as well. The linkers are only 6 amino acids in length, 
but a engineered protein consisting of two AraC DBDs connected by flexible 13- or 19-
residue linkers bound to the adjacent araI1 and araI2 half-sites. This suggests that in the 
absence of arabinose, the rigid orientation of the DBDs is what prevents binding to araI1-
araI2, leaving the protein to form the repression loop by binding to araO2-araI1 instead 
(Harmer, Wu, & Schleif, 2001). 
 The mechanisms by which arabinose binding shifts AraC from DNA looping to 
binding to the adjacent araI1-araI2 half-sites are incompletely understood. My work has 
consisted of three different approaches to research regulation of the arabinose operon by 
AraC. All three approaches share the overarching objective of understanding AraC’s 
structure and its function. The dual inducing-repressing role that AraC plays makes the 
arabinose operon in E. coli different from many other model systems, such as the lac 
operon. The simplicity of the arabinose operon’s regulation at the macromolecular level 
makes it an excellent system for studying gene expression using several approaches, 
including biophysical, biochemical, and genetic studies. The principles demonstrated in 
the arabinose operon can be applied to transcriptional regulation across many species. 
Furthermore, if sufficient molecular understanding is reached, the allosteric principles in 
AraC can be used to engineer other proteins, as has already been crudely done in one 
instance (R. Schleif, 2003). 
 Despite the overall simplicity of the arabinose operon, the AraC protein has been 




decades have failed to yield crystals of full-length AraC that can be used for X-ray 
diffraction (R. Schleif, 2010). The dimerization domain has been successfully crystallized 
in the absence and presence of arabinose (Soisson et al., 1997; Weldon, Rodgers, Larkin, 
& Schleif, 2007). The DNA-binding domains resist crystallization, but their structure was 
determined by NMR (Rodgers & Schleif, 2009). AraC’s regulation of transcription seems 
to involve interaction between the dimerization domain and DNA-binding domains, so 
knowledge of the DD and DBD structures isolated from each other is insufficient to form 
a comprehensive understanding of AraC. Thus, new approaches are required to study the 
protein. I have used biochemical, in vivo, and genetic assays not only to investigate AraC, 
but also to provide tools that will aid future studies – both within the arabinose operon 






CHAPTER 2: MUTAGENESIS IN THE LOOP REGION 
Introduction (Chapter 2) 
 Previous studies have shown that the orientation of the DNA-binding domains 
(DBDs) in AraC influences whether the protein induces or represses transcription from 
the PBAD and PC promoters (Wu & Schleif, 2001a). The orientation of the DBDs is 
apparently controlled by the approximately 18-residue N-terminal arms of each 
monomer. In the absence of arabinose, the arms are postulated to interact with the DBDs, 
holding them in a sufficiently rigid conformation that formation of a DNA loop is 
favored. Upon the binding of arabinose, the arms adopt a different conformation, freeing 
the DNA-binding domains such that they reorient and bind to the adjacent araI1 and araI2 
half-sites (R. Schleif, 2010). Not surprisingly, mutation in the arms or deletion of the 
arms results in an inability of the protein to repress transcription. Without the arm 
functioning properly, AraC binds araI1-araI2 and induces transcription by default. As this 
induction does not require arabinose, the expression is called constitutive (Saviola, 
Seabold, & Schleif, 1998). 
 The crystal structure of AraC’s DD in the presence of arabinose shows that the 8-
residue inter-domain linker found on each monomer (residues 167-174) lies proximal to 
both the N-terminal arm and the loop between the two α-helices of the opposite monomer 
(Figure 2). Recent results indicate that the linker changes structure upon the binding of 
arabinose to AraC (Malaga et al., 2016). 
 The loop constitutes residues 143-146. Although short, the relatively unstructured 
loop could interact with the opposite linker and help to orient the DBD in its repressing or 




binding. The goal of my study was to observe whether there is a conformational change 
in the loop upon the binding of arabinose by labeling a loop residue for use in 
fluorescence anisotropy experiments. 
 
Figure 2. Crystal structure of the AraC dimerization domain when bound to arabinose. One arm 
(red), one loop (yellow), and one linker (cyan) are labeled. The loop lies between the arm of the same 
monomer and the linker of the opposite monomer (Soisson et al., 1997). A conformational change in the 
arm could be translated through the loop to the opposite linker, affecting the orientation of the DNA-
binding domain attached to the linker. 
 
 AraC has been previously labeled with 5-({2-[(iodoacetyl)amino]ethyl}amino)-
naphthalene-1-sulfonic acid (IAEDANS) on cysteine residues introduced into the 
interdomain linker (Malaga et al., 2016). The fluorescent label can be used in subsequent 
anisotropy experiments. To introduce IAEDANS into the loop, I mutated residues E144 
and G145 to cysteine, providing a labeling site for the fluorophore. Then, I overexpressed 
and purified the mutant proteins. 
 The resulting proteins did not retain functionality, implying that the loop cannot 
tolerate cysteine residues. Randomizing residues 143-146 yielded non-functional AraC 




findings suggest that the exact amino acid sequence of the loop may not be important for 
AraC function, but not all mutations are possible. The function of the loop in the AraC 
response to arabinose seems to be small, if it plays any role at all. 
 
Materials and Methods (Chapter 2) 
Plasmids 
The pBAD-GFP (ampr) plasmid was previously described as pBAD-AraC-GFP 
(Timmes, Rodgers, & Schleif, 2004). The plasmid was briefly sold by Clontech® 
(Mountain View, CA). It contains the GFP gene driven by the PBAD promoter, the araC 
gene driven by the PC promoter, and the ampicillin resistance gene β-lactamase (Figure 
3). 
 
Figure 3. The pBAD-GFP plasmid. 
 
The pET21-DD (ampr) plasmid was previously created, referred to as AraCTF 
(Weldon et al., 2007). The plasmid allows for the overproduction of the dimerization 




The pET24d (kanr) plasmid was previously created for the overexpression of full-
length AraC protein (Rodgers & Schleif, 2009). 
The pWR03 (ampr) plasmid was previously created by cloning a DNA fragment 
containing the entire AraC coding region (nucleotides 1-873) into the NcoI and SacI sites 
of pSE380, obtained from Invitrogen (San Diego, CA). 
 
Strains 
Competent DH5α cells were obtained from Invitrogen (San Diego, CA). 
BL21(DE3) cells were used to overexpress AraC protein with the pET21-DD and 
pET24d plasmids (Studier, Rosenberg, Dunn, & Dubendorff, 1990). Competent 
BL21(DE3) cells were originally obtained from Invitrogen (San Diego, CA). 
SH321 (F-, ΔaraC-leu1022 Δlac74, galK-, strr) cells lack a chromosomal copy of 
AraC, as described previously (Hahn, Dunn, & Schleif, 1984). 
SH10 (F+, araC:lacZ fusion, leu-strr, Δlac araD-) cells contain the lacZ gene 




 Yeast tryptone (YT) was used for rich medium as previously described, both for 
plates and liquid cultures. Plates were made with 15 grams of agar per liter. (R. F. Schleif 
& Wensink, 1981). To screen cells using a single sugar source, minimal media were 
used: either A+B or M10, as previously described (R. F. Schleif & Wensink, 1981). 




MgSO4 (1 mM), and either arabinose or glycerol (2 mg/mL). IPTG was used at a 
concentration of 1 mM unless otherwise indicated. Antibiotics were used at the following 




 Cells were grown at 37 ˚C unless otherwise indicated. For liquid media, cells 
were grown in a shaker to approximately stationary phase unless otherwise indicated. 
Typical growth duration was 1 day on YT medium and 2-4 days on minimal media. 
 
Site-Directed Mutagenesis 
 The Agilent Technologies QuikChange™ protocol for oligonucleotide-directed 
mutagenesis was followed for all reactions. After thermocycling, the reaction mixture 
was incubated with DpnI (1 µL, 37 ˚C, 2 hours) obtained from New England Biolabs® 
(Ipswich, MA) to digest any parental (methylated) DNA. Primers were ordered from 
Integrated DNA Technologies (Coralville, IA). 
 
Transformation 
 Plasmid DNA (1-2 µL) was mixed with 50 µL competent E. coli cells (various 
strains) and incubated on ice for 30 min. Cells were subjected to heat-shock (42 ˚C, 20-45 
seconds) and promptly returned to ice (2 min). YT medium (500 µL) was added, and 




recovery, cells were either sterilely spread onto appropriate plates or used to inoculate 
liquid media (YT unless otherwise indicated). 
 
Plasmid DNA Extraction 
 Plasmid DNA was extracted from cells using the Promega Wizard® Plus SV 
Minipreps DNA Purification System: Cells were used to inoculate 5 mL liquid YT media 
supplemented with appropriate antibiotics and other nutrients if necessary. Tubes were 
incubated until the cells reached sufficient growth for sequencing (37 ˚C, approx. 18 
hours). Cells were spun down (3000 RPM, 10 min), and plasmid DNA was extracted 




 Plasmid DNA (approx. 650 ng) was sent to GENEWIZ® (South Plainfield, NJ) 
for sequencing with the appropriate primer. 
 
pET21-DD Protein Overexpression and Purification 
 Mutant protein was overexpressed and purified using the pET21-DD vector 
essentially as described (Weldon et al., 2007). The E144C and G145C mutations were 
first introduced into the araC gene of pET21-DD. The primer sequence used to generate 
E144C was 5’-GCCGGGCAAGGGTGCGGGCGCTATTCGG-3’ and its complement. The primer 
sequence used to generate G145C was 5’-CCGGGCAAGGAGAATGCCGCTATTCGGAG-3’ 




cells and plated onto YT/amp. A starter culture was generated using 5 mL YT/amp 
inoculated with a single colony from the plate, and cells were grown overnight. Two 500 
mL YT/amp flasks were inoculated using the starter culture and grown to A550 = 0.8-1.0. 
IPTG (0.4 mM) was added to induce AraC overexpression, and growth continued for an 
additional 5 hours. 
 Cells with overexpressed protein were harvested via centrifugation and 
resuspended in lysis buffer (0.1 M NaCl, 15 mM Tris-HCl pH 8, 10 mM MgCl2, 5 mM 
arabinose, 5% glycerol, 10 µg/mL DNase, 10 µg/mL RNase). Cells were lysed, then 
centrifuged (15000 RPM, 15 min). The supernatant was passed through a Ni2+-NTA 
affinity chromatography column equilibrated with wash buffer (15 mM Tris-HCl pH 8, 
100 mM NaCl, 5 mM arabinose, 10 mM imidazole). The flow-through was collected and 
passed through the column a second time. The column was washed with wash buffer until 
eluate A280 was below 0.05. AraC was eluted using elution buffer (15 mM Tris-HCl pH 8, 
10 mM NaCl, 5 mM arabinose, 1 M imidazole). 
 The eluate was incubated with 1 µg trypsin per mg of estimated protein (4 ˚C, 16 
hours), then soybean trypsin inhibitor was added in equimolar concentration to inhibit the 
digest. Final protein purification was achieved using high-performance liquid 
chromatography. Protein was bound to the column without salt (15 mM Tris-HCl pH 8, 








GFP Fluorescence Assay to Measure PBAD Induction 
Three different plasmids were transformed into the SH321 cell line: pBAD-GFP 
WT, pBAD-gfp- (WT AraC sequence but non-functional GFP), and pBAD-GFP with the 
mutation 143-146RIRY (“RIRY”). Cells were grown overnight in 5 mL of liquid 
YT/amp media, both with and without arabinose. A fluorescence-based AraC induction 
assay was performed essentially as previously described (Timmes et al., 2004). Following 
growth, OD was calculated by measuring Abs600. Cells were lysed with detergent and 
excited at 395 nm; GFP emission was measured at 508 nm, and cell density was 
measured proportional to emission at 395 nm. One 10%-transmittance neutral-density 
filter was used to measure cell density at 395 nm. 
Calculations were performed as follows: The values from a buffer blank were 
subtracted from values for cell samples. The ratio of [508nmsample]/[395nmsample] was 
determined. Normalized fluorescence was calculated relative to the pBAD-GFP WT 
Ara+ sample using the following formula: [Ratiosample]/[Ratiowt-Ara+].  
 
PC Repression Assay 
A repression assay was performed based on the protocol of Zhang and Bremer 
(1995), with solutions made as described. The assay uses ortho-nitrophenyl-β-galactoside 
(ONPG) to detect β-galactosidase activity through formation of the yellow product ortho-
Nitrophenol. If AraC (encoded on the pBAD-GFP plasmid for this assay) maintains 
repressing ability, then SH10 cells (containing the PC-lacZ fusion) should form little 
colored product in the absence of arabinose due to the lack of lacZ transcription. The 




 Beta-galactosidase levels were measured as described, with some modifications 
(R. F. Schleif & Wensink, 1981). SH10 cells (with appropriate plasmids if necessary) 
were grown to stationary phase in YT medium; Abs600 was recorded. Cells (20 µL) were 
added to permeabilization solution (80 µL) and incubated at 30 ˚C for 25 min. Cells 
remained at 30 ˚C, and substrate solution (600 µL) was added. After sufficient yellow 
color was observed, stop solution (700 µL) was added, and samples were kept at room 
temperature. The time between adding substrate solution and stop solution was noted. 
Samples were spun in a microcentrifuge (maximum speed, 10 min). The Abs420 of the 
supernatant was recorded. 
 Miller Units were calculated using the formula: M.U. = [1000*Abs420] / 
[t*v*Abs600], where t represents the reaction time (mins) for each sample, and v is the 
volume of cells used in milliliters (for this study, 20 µL). Higher Miller Units indicates an 
inability to repress transcription from PC. 
 
Results and Discussion (Chapter 2) 
The E144C Mutation in AraC DD Produced Aggregating Protein 
 To label the loop with IAEDANS, the mutation E144C was introduced to the 
araC gene of the pET21-DD vector, which encodes the DD of AraC and provides 
ampicillin resistance. Mutations were introduced following the QuikChange™ protocol. 
Plasmids containing the mutated DNA were transformed into competent DH5α E. coli 
cells and plated on YT/amp. Isolated colonies were grown in liquid YT/amp, and their 
plasmid DNA was purified and sent for sequencing to verify successful mutagenesis. 




and plated onto YT/amp. Cells were grown in liquid culture, induced to overexpress the 
dimerization domain, and lysed. 
 While attempting to purify the E144C AraC protein from the lysate with affinity 
chromatography, significant elution was not achieved. The introduction of the cysteine at 
residue 144 likely disrupted protein folding, causing aggregation. Alternatively, an 
exposed cysteine could have still resulted in aggregated protein even if folding was not 
affected due to the formation of disulfide bonds. Dithiothreitol (DTT; 10 mM) was 
introduced to maintain a reducing environment and prevent unwanted disulfide bonds 
from forming, but sufficient protein elution was still not achieved. This finding suggests 
that introducing a cysteine at residue 144 may affect AraC structure too much for further 
study. 
 
The E144C Mutation in Full-Length AraC Produced Non-Functional Protein in vivo 
 To investigate the effects of the E144C mutation in vivo, E144C was introduced 
into the pET24d plasmid, which encodes full-length AraC and provides kanamycin 
resistance. Mutagenesis was performed using the standard QuikChange™ protocol, and 
isolated colonies were selected for sequencing. Verified DNA was transformed into 
competent SH321 cells, which lack a chromosomal copy of araC. Colonies were dual-
spotted onto minimal nutrient plates containing either glycerol (A+B/gly/kan) or 
arabinose (A+B/ara/kan) as their sole carbon source. All cells would be expected to grow 
on glycerol, but only transformants with functional AraC proteins should grow on 




colonies containing the E144C mutation in araC grew on glycerol but not arabinose, 
confirming that the E144C mutation results in a non-functional AraC protein. 
 
The G145C Mutation in AraC DD Also Produced Aggregating Protein 
 Because purification of the E144C mutant was unsuccessful, I instead aimed to 
produce the G145C mutant in pET21-DD for use in subsequent characterization 
experiments. No elution of protein was achieved from Ni2+ affinity chromatography. The 
purification was attempted with the reducing agents DTT (10 mM) and Tris(2-
carboxyethyl)phosphine (TCEP; 1 mM) to prevent unwanted disulfide bonds, but without 
success. Increasing the concentration of imidazole from 1 M to 3 M also did not result in 
elution of the protein. 
 Analysis with SDS-PAGE demonstrated that protein overexpression had been 
achieved, but only 30% of the protein remained in the supernatant after centrifugation; 
the remaining 70% was aggregated in the discarded pellet. No elution was obtained from 
the Ni2+ column because most of the protein remained bound to the column beads. The 
insolubility of both the E144C and G145C mutants in AraC DD, in addition to the loss of 
AraC function in pET24d E144C, suggests that it may not be possible to introduce 
cysteine mutations into the loop for subsequent characterization experiments. 
 
Randomizing Residues 143-146 Demonstrated that the Loop Can Be Mutated without 
Compromising Function 
 To investigate whether any mutations in the AraC loop region are tolerated 




on the pWR03 plasmid, which contains full-length araC and ampicillin resistance. 
Randomization was achieved using QuikChange™ and the following primers: 5’-
CATTAACGCCGGGCAANNNNNNNNNNNNTATTCGGAGCTGCTG-3’ and its complement. 
Mutated DNA was transformed into the araC– SH321 cell line. Randomized colonies 
were dual-spotted onto A+B/gly/amp and A+B/ara/amp. 
 All colonies grew on A+B/gly/amp. Some, but not all, randomized colonies grew 
on A+B/ara/amp, indicating that mutations in the loop can still yield functional AraC 
protein. One colony was used for plasmid DNA extraction and sequencing of the araC 
gene; the amino acid sequence of residues 143-146 was PIDS, while the wild-type 
sequence is GEGR. The sequenced plasmid also had an early STOP codon in place of 
residue 281, in addition to the PIDS mutation. The early STOP281 codon did not affect 
protein function; this is consistent with previous studies, which found that some 
premature truncations late in the AraC primary sequence show no abnormal phenotype 
(Eustance & Schleif, 1996). The ability of the PIDS mutant to grow on A+B/ara/amp 
demonstrates that mutating the loop region of araC can still result in a functional protein. 
To increase support of this finding, a similar randomization experiment was carried out in 
another araC-encoding plasmid, pBAD-GFP. 
 The pBAD-GFP plasmid contains the entire ara regulatory region with GFP 
under control of the PBAD promoter (in place of araBAD) and araC under control of the 
PC promoter. The plasmid confers ampicillin resistance. Randomization of residues 143-
146 was repeated in this plasmid as described for pWR03. If grown on arabinose, cells 





 The loop residues (143-146) in the araC gene of pBAD-GFP were mutated 
similarly to the randomization in pWR03. The primers used for the randomization were 
5’-
GGCAAATCATTAACGCCGGGCAANNNNNNNNNNNNTAATCGGAGCTGCTGGCGATAAATC-3’ 
and its complement. Mutated plasmids were transformed into SH321 cells, and resulting 
colonies were dual spot-tested for growth on A+B/gly/amp and A+B/ara/amp. All 
colonies, including wild type, had comparable growth on A+B/gly/amp. Some, but not 
all, mutant colonies grew on A+B/ara/amp. Select colonies that grew on A+B/ara/amp 
had their pBAD-GFP plasmids sequenced (Table 1). 
 
Table 1. The AraC sequence in residues 143-146 and growth on minimal arabinose media after 
randomization of the nucleotides encoding residues 143-146 in araC of pBAD-GFP. 
Sequence in AraC Residues 143-146 Relative Growth on A+B/ara/amp 







“Full” growth indicates that growth was comparable to the growth of wild type cells on A+B/gly/amp. 
  
 The findings in pBAD-GFP support the results from using the pWR03 plasmid. 
Some mutations in the loop were found to eliminate AraC functionality in vivo. No 
cysteine-containing mutants with growth on minimal arabinose media were identified, 
suggesting that the presence of cysteine in the loop may cause the loss of AraC function. 
However, the growth of certain mutant colonies on minimal arabinose demonstrated that 






The 143-146RIRY Loop Mutant Had 81% of WT PBAD Induction 
Of the mutants found in the previous screen, pBAD-GFP with RIRY substituted 
for residues 143-146 (“RIRY”) was chosen for further study. RIRY was selected as a 
representative plasmid that encoded a functional araC despite mutation in the loop 
residues. 
Three different plasmids were transformed into the SH321 cell line: pBAD-GFP 
WT, pBAD-gfp- (WT AraC sequence but non-functional GFP), and RIRY. Following 
growth, the GFP fluorescence assay was performed (Table 2). 
 
Table 2. The RIRY mutant induces PBAD to approximately 81% of WT AraC in the presence of 
arabinose. 
Sample 395 nm 508 nm Ratio OD 395 nm/OD Norm. Fluorescence 
WT Ara+ 386181 1061720 2.75 9.7 39649 1.00 
WT Ara- 439605 137212 0.31 7.6 57919 0.11 
gfp- Ara+ 359087 136715 0.38 8.2 43685 0.14 
gfp- Ara- 432063 138105 0.32 7.0 61989 0.12 
RIRY Ara+ 427838 947120 2.21 9.0 47538 0.81 
RIRY Ara- 434285 150310 0.35 7.4 58450 0.13 
Values under 395 nm and 508 nm represent single-photon counts. 395 nm measures cell density, while 508 
nm measures GFP fluorescence. “Ratio” was calculated using the following formula: 
[508nmsample]/[395nmsample]. OD is the absorbance of the cells at 600nm before lysis. Normalized 
fluorescence (“Norm. Fluorescence”) was calculated using the following formula: [Ratiosample]/[Ratiowt-
Ara+]. 
 
The RIRY mutant, in the presence of arabinose, induced GFP fluorescence 
approximately 81% of the WT in arabinose. The background fluorescence, shown by the 
pBAD-gfp- samples, was approximately 12-14%. The ratio of photon counts at 575 nm to 
OD (Abs600) should be approximately equal within the same sample of cells. However, 
lysing the cells may have affected the emission. The approximately equivalent calculated 
normalized fluorescence values for uninduced wild type cells (WT Ara-) and gfp- cells 




overlap with cell autofluorescence, making the assay lack precision that would be 
required for thorough characterization of mutant AraC function. This problem will be 
addressed in Chapter 2 of the thesis. Despite the imprecision, this assay still demonstrates 
that the RIRY mutant retains significant PBAD induction ability. Future studies could 
repeat the GFP assay to observe the induction achieved with other AraC loop mutants. 
 
Mutants of AraC in Residues 143-146 Maintained the Ability to Repress Expression 
To observe the ability of loop mutants to repress transcription, pBAD-GFP WT, 
pBAD-gfp-, and pBAD-GFP plasmids with the following mutations of AraC residues 
143-146 were transformed into the SH10 cell line: RIRY, TSGF, TATP, and GARP. 
Transformants were grown in 5 mL of liquid YT/amp overnight. A sample of plain SH10 
cells (No Vector) was also grown in 5 mL YT, but without ampicillin. Cells were used in 
a repression assay at 30˚C, which has been previously performed with AraC (Reed & 
Schleif, 1999). 
The repression assay was conducted using two samples of each cell type. Higher 
Miller Units indicates an inability to repress transcription. The results of the repression 











Table 3. AraC proteins with mutations in residues 143-146 retained the ability to repress 
transcription from PC. 
Sample Abs600 Time (min) Abs420 Miller Units 
No Vector 1 7.12 33.2 1.34 283.78 
No Vector 2 7.12 33.2 1.46 308.13 
GFP WT 1 5.22 63.5 0.14 21.12 
GFP WT 2 5.22 63.5 0.15 22.63 
gfp- 1 6.00 63.5 0.13 16.80 
gfp- 2 6.00 63.5 0.13 16.67 
RIRY 1 6.40 63.5 0.26 32.36 
RIRY 2 6.40 63.5 0.26 31.50 
TSGF 1 6.56 63.5 0.16 19.69 
TSGF 2 6.56 63.5 0.17 20.41 
TATP 1 5.92 63.5 0.09 11.31 
TATP 2 5.92 63.5 0.08 11.04 
GARP 1 6.56 63.5 0.10 11.76 
GARP 2 6.56 63.5 0.10 11.52 
Miller Units were calculated using the formula: M.U. = [1000*Abs420] / [t*v*Abs600], where t represents 
the reaction time (mins) for each sample, and v is the volume of cells (20 µL). Higher Miller Units 
indicates an inability to repress transcription. 
 
RIRY was the only mutant with higher Miller Units than the GFP WT control, 
and the difference between the values – approximately 32 for RIRY and 22 for WT – was 
marginal. All other mutants displayed repression ability comparable to or better than the 
WT. These data indicate that AraC with randomizations within the loop region retains the 
ability to repress PBAD through DNA looping. 
 
Summary and Conclusion of Loop Experiments (Chapter 2) 
 Neither the E144C nor the G145C mutant in pET21-DD could be purified, likely 
due to misfolding, thus precluding further study such as fluorescence anisotropy 
experiments. Consistent with this result, the E144C mutant of AraC in pET24d 
transformed into SH321 cells exhibited no growth on minimal arabinose media, 
suggesting that an introduced cysteine in the loop could affect protein structure and/or 




functionality is preserved when the residues are mutated and AraC function is assessed in 
vivo. Furthermore, activity based on GFP fluorescence indicated that the RIRY mutant 
can induce PBAD transcription to approximately 81% of the level of WT. A repression 
assay of PC demonstrated that all four mutants of the 143-146 residues maintained the 
ability to repress transcription. 
These findings suggest that the loop may not play a significant role in the 
conformational change of AraC upon binding of arabinose, or that the role of the loop is 
not significantly sensitive to its sequence. Nevertheless, the introduction of cysteine into 
the loop seems to significantly affect AraC structure and function. Few labeling options 
other than cysteine labeling exist, so attempting to introduce a cysteine into the loop to 
observe how the loop may change upon the binding of AraC to arabinose may still be 
worthwhile. Modifying the purification method or introducing a cysteine in residues 




CHAPTER 3: DEVELOPING A FLUORESCENCE-BASED ASSAY TO 
MEASURE ARAC FUNCTION 
Introduction (Chapter 3) 
 In the presence of arabinose, AraC induces the expression of the araBAD genes, 
which encode the enzymes responsible for metabolizing arabinose. araA encodes L-
arabinose isomerase, which catalyzes the conversion of L-arabinose to L-ribulose. The 
arabinose isomerase assay has been used to measure the activity of AraC in vivo, as 
previously described (R. F. Schleif & Wensink, 1981). However, the assay is subject to 
substantial errors and possesses a narrow range of linearity. The pBAD-GFP construct 
contains araC under control of the PC promoter and GFP under control of the PBAD 
promoter. pBAD-GFP fluorescence assays have been used to measure AraC activity, as 
in Chapter 1. However, the GFP fluorescence assay is not sufficiently sensitive for 
quantitation of PBAD activities below approximately 25% of full induction; this is due to a 
high fluorescence background of cellular components in the same wavelength range as 
emission from GFP. Therefore, I developed an assay to measure the expression off the 
PBAD promoter through the red fluorescent protein, mCherry, whose emission is in a range 
with much less interference from cellular components. 
 
Materials and Methods (Chapter 3) 
Preparation of mCherry 
 The plasmid pME-mCherry was obtained from the lab of Marnie Halpern 
(Carnegie Institute of Embryology, Baltimore, MD). The mCherry gene was amplified 
from pME-mCherry using PCR (Agilent Technologies, Santa Clara, CA), simultaneously 






 To prepare the mCherry gene for cloning into the pBAD-mCherry plasmid, the 
PCR product was triple-digested with the restriction enzymes NheI, EcoRI, and DpnI, all 
obtained from New England Biolabs® (Ipswich, MA), following the protocols indicated. 
DpnI was used to digest parental DNA. 
 
Preparation of the pBAD-GFP Plasmid 
 The pBAD-GFP plasmid was double-digested with the restriction enzymes NheI 
and EcoRI, obtained from New England Biolabs® (Ipswich, MA), following the protocols 
indicated. The product was treated with thermosensitive alkaline phosphatase (TSAP; 
Promega, Madison, WI), following the protocols indicated, to prevent regeneration of the 
parental plasmid in the subsequent ligation step. 
 
Ligation 
 The digested mCherry product and the TSAP-treated pBAD-GFP plasmid were 
ligated following the Quick Ligation™ protocol from New England Biolabs® (Ipswich, 
MA). 
 
Final QuikChange™ to Restore mCherry 
 A final QuikChange™ reaction (Agilent Technologies, Santa Clara, CA) was 
performed to restore the original coding sequence of the mCherry gene, which was earlier 




primers used for the final QuikChange™ correction reaction were 5’-
GGAGATATACATATGGTGAGCAAGGGCGAGG-3’ and its complement. 
 
mCherry Fluorescence-Based Assay of AraC Function 
 pBAD-mCherry was transformed into competent SH321 cells and plated onto 
YT/amp. A single colony was used to inoculate one 5 mL tube of liquid YT/amp 
(“uninduced”) and one 5 mL tube of liquid YT/amp supplemented with arabinose 
(“induced”). SH321 cells without any plasmid (“Plain SH321”) were grown in 5 mL 
liquid YT. Cells were grown to stationary phase, then placed on ice. Measurements were 
taken using a fluorimeter (50 µL cells in 3 mL M10 buffer) (R. F. Schleif & Wensink, 
1981) with two detectors. Cells were excited with 575 nm light. Detector A measured 
emission at 575 nm to obtain cell density, and detector B measured emission at 605 nm to 
observe mCherry fluorescence. Two 10%-transmittance neutral-density filters were 
placed on detector A. No polarizers were used. A buffer blank was also measured. 
 Calculations were performed as follows: values from the buffer blank were 
subtracted from all sample measurements. The ratio of [605nmsample]/[575nmsample] was 
determined. The “ratio” value for Plain SH321 cells was subtracted from the “ratio” value 
for uninduced and induced cells (“Minus SH321”). Finally, induction ratio (“induction”) 
was calculated using the following formula: [Minus SH321induced]/[Minus SH321uninduced]. 
 
Results and Discussion (Chapter 3) 
 An induction ratio of approximately 50 was achieved; typical values found for 





Table 4. Typical values from the pBAD-mCherry fluorescence assay of AraC function. 
Sample 575 nm 605 nm Ratio Minus SH321 Induction 
Plain SH321 225000 12000 0.053 
  
Uninduced 180000 25000 0.139 0.086 
 
Induced 125000 550000 4.4 4.347 50.54 
Values under 575 nm and 605 nm represent single-photon counts. 575 nm measures cell density, while 605 
nm indicates mCherry fluorescence. An induction ratio of approximately 50 was able to be achieved. 
“Ratio” corresponds to [605nmsample]/[575nmsample]. “Minus SH321” corresponds to [Ratiosample – RatioPlain 
SH321]. Induction corresponds to [Minus SH321induced]/[Minus SH321uninduced]. 
 
 The creation of the pBAD-mCherry plasmid and the development of the 
fluorescence-based assay provides an alternative to arabinose isomerase assays. The 
fluorescence assay provides a quick method to assess AraC function, indicated by 
transcription from PBAD and resulting mCherry fluorescence when cells are grown with 
arabinose. Previously, GFP fluorescence has been used, as documented in Chapter 1 of 
this thesis and previous studies (Timmes et al., 2004). Substitution of GFP for mCherry 
allows for a more precise assay, minimizing the magnitude of unwanted cell 
autofluorescence. Future studies should refine this method further by comparing 
induction ratios of well-characterized AraC mutants (on the pBAD-mCherry plasmid, in 






CHAPTER 4: USING GENETICS TO UNDERSTAND PROTEIN STRUCTURE 
THROUGH COMPLEMENTING MUTATIONS 
Introduction (Chapter 4) 
 The structure and function of proteins are intricately related. Simply 
understanding a protein’s structure can sometimes shed light on how the protein acts 
mechanistically. In the case of AraC, inter-domain interactions are thought to dictate the 
protein’s behavior. However, due to AraC’s resistance to crystallization, these structural 
features cannot be detected through classical methods for structure determination. Here, I 
demonstrate an approach that, when refined, can use simple genetics to gain structural 
information about AraC. Additionally, this approach should be readily adaptable to other 
proteins. 
Single amino acid substitutions in proteins have the potential to reduce protein 
function. Introducing a different amino acid alters local biochemistry, which can have 
subsequent consequences on protein structure, generating a loss-of-function mutation. 
However, a second-site correcting mutation can permit a reversion of the altered protein’s 
biochemistry to its original nature, most likely by restoring local structure and thereby 
restoring protein function. Amino acid changes in a protein generally induce local 
structural changes. Therefore, it seems likely that second site suppressors or correcting 
mutations will lie close in the protein’s three-dimensional native structure to the original 
mutation. 
Studies dating back to the 1990s have documented occasional second-site amino 
acid substitutions in residues proximal to the originally substituted residue (Chen, Dean, 




Peinado, & Mueller, 1996). Recently, the scientific community has realized that this 
complementing phenomenon can be exploited to provide valuable assistance when 
predicting the structures of proteins from their amino acid sequences. Current work has 
been able to use only sequencing data in conjunction with the Rosetta protein folding 
program to quite accurately predict the three-dimensional structures of folded peptides 
(Bitbol, Dwyer, Colwell, & Wingreen, 2016; Ovchinnikov et al., 2017). These findings 
provide confidence that complementing amino acid changes often lie near each other, if 
not directly interact. The identification of complementing substitutions in AraC could 
provide information about inter-domain interactions. In turn, these interactions could 
explain the protein’s conformational changes upon the binding of arabinose and how the 
changes result in the induction or repression of transcription. This approach requires a 
means of mutating residues and quickly assessing protein function. 
 
Materials and Methods (Chapter 4) 
Plasmids 
The pBAD-GFP (ampr) plasmid was previously described as pBAD-AraC-GFP 
(Timmes et al., 2004). The plasmid was briefly sold by Clontech® (Mountain View, CA). 
It contains the GFP gene driven by the PBAD promoter, the araC gene driven by the PC 
promoter, and the ampicillin resistance gene β-lactamase. 
The pCCN-GFP and pCCN-mCherry (kanr) plasmids were derived from iGEM 
pSB2K4 (Cambridge, MA) and named CCN for their controllable copy number. The 
plasmids contain the full PBAD regulatory region from pBAD-GFP, including the araC 




unpublished). pCCN-GFP and pCCN-mCherry can be maintained at single copy number 
with elevated levels of lac repressor (LacI). Alternatively, they can be increased to high 
copy number for sequencing if cells containing pCCN are induced with Isopropyl β-D-1-
thiogalactopyranoside (IPTG). 
The pSE380 (ampr) plasmid was obtained from Invitrogen (San Diego, CA). 
pSE380 is a high copy number plasmid containing the lacI gene, used in this study to 
keep pCCN-GFP and pCCN-mCherry at presumably single copy number. 
 
Strains 
SH321 (F-, ΔaraC-leu1022 Δlac74, galK-, strr) cells lack a chromosomal copy of 
AraC, as described previously (Hahn et al., 1984). 
RS321 (SH321 by P1 transduction, with TN10-IQ-lac, cmr::lac) cells contain the 
lacI gene regulated by the lacIQ promoter, used for controlling the copy number of 
pCCN-GFP and pCCN-mCherry (Schleif, unpublished). 
Competent XL1-Red® cells were obtained from Agilent Technologies (Santa 
Clara, CA). These cells contain mutator alleles and have inactivation in three DNA repair 
pathways. As a result, they generate insertions, deletions, and base changes with a 




 Yeast tryptone (YT) was used for rich medium as previously described, both for 




& Wensink, 1981). To screen cells using a single sugar source, minimal media were 
used: either A+B or M10, as previously described (R. F. Schleif & Wensink, 1981). 
Minimal media were supplemented with leucine (50 µg/mL), vitamin B1 (10 µg/mL), 
MgSO4 (1 mM), and either arabinose or glycerol (2 mg/mL). IPTG was used at a 
concentration of 1 mM unless otherwise indicated. Antibiotics were used at the following 




 Cells were grown at 37 ˚C unless otherwise indicated. For liquid media, cells 
were grown in a shaker to approximately stationary phase unless otherwise indicated. 
Typical growth duration was 1 day on YT medium and 2-4 days on minimal media. 
 
Site-Directed Mutagenesis 
 The Agilent Technologies QuikChange™ protocol for oligonucleotide-directed 
mutagenesis was followed for all reactions. After thermocycling, the reaction mixture 
was incubated with DpnI (1 µL, 37 ˚C, 2 hours) obtained from New England Biolabs® 
(Ipswich, MA) to digest any parental (methylated) DNA. Primers were ordered from 
Integrated DNA Technologies (Coralville, IA). 
 
Transformation 
 Plasmid DNA (1-2 µL) was mixed with 50 µL competent E. coli cells (various 




seconds) and promptly returned to ice (2 min). YT medium (500 µL) was added, and 
cells were allowed to recover without antibiotics (37 ˚C, approx. 1 hour). Following 
recovery, cells were either sterilely spread onto appropriate plates or used to inoculate 
liquid media (YT unless otherwise indicated). 
 
Plasmid DNA Extraction 
 Plasmid DNA was extracted from cells using the Promega Wizard® Plus SV 
Minipreps DNA Purification System: Cells were used to inoculate 5 mL liquid YT media 
supplemented with appropriate antibiotics and other nutrients if necessary. Tubes were 
incubated until the cells reached sufficient growth for sequencing (37 ˚C, approx. 18 
hours). Cells were spun down (3000 RPM, 10 min), and plasmid DNA was extracted 




 Plasmid DNA (approx. 650 ng) was sent to GENEWIZ® (South Plainfield, NJ) 
for sequencing with the appropriate primer. 
 
Developing a System to Screen for Mutants 
The plasmid pBAD-GFP contains the gene encoding GFP driven by the PBAD 
promoter, the araC gene driven by the PC promoter, and the ampicillin resistance gene β-
lactamase (Figure 3). The E. coli strain SH321 lacks a chromosomal copy of araC. 




plasmid) can be easily mutagenized and sequenced, while the growth of cells and protein 
function can be simultaneously observed in vivo. Because AraC induces the PBAD 
promoter in the presence of arabinose, AraC function should result in proportional 
induction of GFP from PBAD. Thus, GFP fluorescence can be used as an indication of 
AraC functionality. 
In addition to GFP, this system provides another means of assessing AraC 
function: cell growth. Functional AraC is necessary for E. coli cells to metabolize 
arabinose, since it is the regulatory protein of the operon and is necessary to induce the 
transcription of araBAD. If cells are grown in minimal media containing arabinose as the 
sole sugar source, then AraC function should also be proportional to cell growth – in 
addition to GFP induction – because AraC is needed to metabolize arabinose. The better 
that cells can metabolize arabinose, the better they can grow. The dual role of the 
plasmid-based AraC provides two methods of assaying activity: cell growth and whole-
cell GFP fluorescence. Notably, both growth and GFP fluorescence are qualitative 
measures of activity unless a fluorescence assay is performed. Cell growth and 
fluorescence can be used to indicate whether AraC is relatively functional or non-
functional, but should not be used quantitatively. For the purposes of identifying loss-of-
function mutants and corrected mutants, however, a heuristic measure is sufficiently 








Generating Primary Mutations in araC 
pBAD-GFP was mutagenized by transformation into the mutating E. coli strain 
XL1-Red®, which has a random mutation rate approximately 5000-fold higher than 
common strains due to its deficiency in DNA repair pathways. Cells were plated on YT 
media containing 100 µg/mL ampicillin (YT/amp) to select for transformants. Resulting 
colonies were scraped off the plate, and their plasmid DNA was extracted using the 
Promega Miniprep protocol. Extracted plasmids had random mutations throughout due to 
the error-prone DNA polymerase of XL1-Red®. This heterogeneous mixture of plasmids 
was expected to contain some plasmids with loss-of-function mutations in araC. 
 
Identifying Cells with Loss of Function Mutations 
Mutated plasmids were transformed into the araC- cell line SH321; cells were 
grown on YT/amp at 37 ˚C overnight. As a control, wild-type pBAD-GFP was also 
transformed into SH321 cells and grown on YT/amp overnight (“WT cells/colonies”). 
After growth of the mutant colonies, replica plating was performed onto a plate of 
minimal media containing arabinose (2 mg/mL) as the sole sugar source. These plates 
also contained M10 salts, leucine (50 µg/mL), vitamin B1 (10 µg/mL), MgSO4 (1 mM), 
and ampicillin (100 µg/mL) – abbreviated as min/ara/amp. After 2 days of growth at 37 
˚C, colonies on the replica plate were assessed for growth and GFP fluorescence. 
Colonies with decreased growth compared to others were streaked onto a fresh plate of 
YT/amp (incubated at 37 ˚C overnight) to ensure isolation of a single colony. 
Isolated colonies were dual-spotted onto two types of media: min/ara/amp and 




The order is important because the first spot may get more cells than the second. To 
avoid mistakenly identifying a colony as having poor growth on arabinose, it is important 
to spot onto arabinose first. WT colonies were also spotted as a control. After incubation 
for 2 days at 37 ˚C, colony growth and fluorescence was observed; those with decreased 
growth on arabinose (“AraC-”) compared to WT colonies were selected for subsequent 
steps. Fluorescence was used merely as an aid in identifying poorly-growing colonies, 
since a non-fluorescent colony could have a loss-of-function mutation in GFP instead of 
araC. Cell growth was used as the final indication of AraC functionality. 
 
Generating Second-Site Correcting Mutations 
Sterile tubes of 5 mL liquid min/gly/amp were individually inoculated with AraC- 
colonies and grown at 37 ˚C. During this growth, mutations were randomly generated 
throughout the pBAD-GFP plasmids due to the normal error of E. coli DNA polymerase. 
After two days, cells were spun down (3000 RPM, 10 min), resuspended in 100 µL 
min/gly/amp, plated onto min/ara/amp, and grown for approximately 2 days at 37 ˚C. 
Colonies with prominent growth were streaked on YT/amp and incubated at 37 ˚C 
overnight. Isolated colonies were dual-spotted onto min/gly/amp and min/ara/amp, in that 
order. WT colonies were also spotted as a control. After incubation for 2 days at 37 ˚C, 
colonies with WT phenotype (“AraC+” revertants) were selected. 
 
Sequencing AraC+ Revertants 
AraC+ revertant colonies were used to individually inoculate sterile tubes of 5 mL 




(3000 RPM, 10 min), and plasmid DNA was extracted using the Promega Miniprep 
protocol. The plasmid was sequenced to obtain the AraC coding sequence. Sequences 
were analyzed for the presence of a primary and correcting mutation. Figure 4 outlines 
the entire process for generating AraC- mutations and correcting mutations. 
 
Figure 4. Chapter 4 methods overview. pBAD-GFP DNA was passed through the mutating strain XL1-
Red® to generate loss-of-function mutations in araC. Cells with mutations were selected using differential 
growth on minimal ara versus minimal gly media. Plasmid DNA was extracted from cells with poor or no 
growth on ara. Second-site correcting mutations were generated during subsequent cell growth. Colonies 
were spotted on minimal ara and minimal gly once more; plasmid DNA was extracted from cells with WT-
like growth on ara. The extracted DNA was then sequenced and analyzed for the presence of 
complementing mutations. 
 
Results and Discussion (Chapter 4) 
The method described generated mutations in araC on the pBAD-GFP plasmid. 
Sequencing results verified whether mutagenesis screens were successful in generating 
primary and secondary substitutions. The above procedure was repeated three times 
(mutagenesis screens 1-3); however, revertants were not generated in screen 3 (discussed 





Mutagenesis Screen 1 
Five AraC+ revertant colonies were sequenced (Table 5). The screen generated one 
colony with two amino acid substitutions in AraC, two colonies with a single amino acid 
substitution in AraC, and two colonies with WT AraC. 
 
Table 5. AraC+ revertants that were sequenced in mutagenesis screen 1. 
Colony Mutations Amino Acid Changes 
1 81(CAC  CAA) 






12(GGA  AGA) G12R 
3 156(CTT  GTT) 
 
L156V 
4 Wild Type 
 
 
5 Wild Type  
 
H81Q and R146P  
Histidine 81 lies within the β-sheet of AraC’s dimerization domain (DD). 
Previous studies have shown that in the presence of arabinose, the AraC mutant H81P 
induces PBAD at only 20% of the induction seen in WT cells. On the other hand, H81P 
AraC represses PC, the promoter for araC, 100% compared to WT (Wendy Reed, 
unpublished). Because AraC simultaneously controls the transcription off PC and PBAD, 
repression of PC is expected to be reflected by repression of PBAD as well. Arginine 146 
lies in the loop between two α-helices of the DD. The R146P mutant has not been 
documented. However, as discussed in Chapter 1, many mutations in the loop can be 
tolerated without affecting AraC function. 
Given that mutation of H81 has been shown to reduce induction, it is likely that 




second-site correcting mutation, or it could be a trivial mutation that occurred at any 
point, given that the loop has been mutated without functional consequences. Residues 81 
and 146 are both in the dimerization domain, which has a rigid structure that has been 
crystallized. These residues are not proximal to each other, so it is unlikely that they 
would interact directly. It is possible that far-away residues could also complement each 
other, but a more likely explanation is that the R146P mutation is insignificant to AraC’s 
structure and function. Decreased induction due to H81Q could still be sufficient to 
produce WT-like growth with the high copy number pBAD-GFP plasmid, allowing the 
double mutant H81Q/R146P to pass as a pair of complementing mutations. Introducing 




G12 lies on the N-terminal arm of AraC. Previous studies have determined that 
the G12R mutant is constitutive, but inducible (Jennifer Ross, Thesis). In the absence of 
arabinose, G12R induces transcription from the PBAD promoter 100% relative to the 
amount of induction from WT protein in the presence of arabinose. G12R further induces 
transcription to 200% of WT in the presence of arabinose. Without a second mutation, 
this colony is not useful for the study. 
 
L156V 
Residue 156 lies in an α-helix of the DD. Previous studies have determined that 




the absence of arabinose (Schleif, unpublished). Again, without a second mutation, this 
colony is not useful for the study. 
 
WT 
Two colonies were WT in sequence, indicating either that the selection process 
was imperfect, or the original mutations were directly reverted back to WT sequence. In 
mutagenesis screen 1, loose criteria were used to select for AraC- cells; cells with reduced 
growth on min/ara were still considered, as opposed to only considering cells with 
absolutely no growth. WT cells could have passed through the screening process for 
AraC- candidates. Alternatively, the original mutation that produced the AraC- phenotype 
could have reverted back to wild type. 
 
Mutagenesis Screen 2: Stricter AraC- Selection 
In mutagenesis screen 2, I used more rigid AraC- selection criteria. Only cells that 
had no growth on arabinose were pursued for generating AraC+ revertants. Five more 
AraC+ revertants were sequenced (Table 6). The use of strict select criteria for AraC- 
colonies likely caused nonsense or frameshift mutations to be selected for, rather than 
single-amino acid substitutions. Substitutions are less likely to cause severe changes in 
protein function. The problem of selecting for more frameshift and nonsense mutations is 
exacerbated with a high copy number plasmid. At high copy number, a significant but not 
complete loss of AraC function from a substitution can be outweighed by having more 




wild type. Additionally, four colonies in this screen possessed the same genotype; this is 
probably due to the selection of colonies descended from the same transformant. 
 
Table 6. AraC+ revertants that were sequenced in mutagenesis screen 2. 
Colony Mutations Amino Acid Changes 
6 84(CGT  CAT) 






84(CGT  CAT) 




8 84(CGT  CAT) 




9 84(CGT  CAT) 




10 62(CGA  CGT) 




R84H and W104STOP 
Four colonies had the same sequence; two were a pair of revertants from one 
AraC- strain, and the other two were a pair of revertants from a different AraC- strain. 
Because there are limited options for residues close enough to complement an AraC- 
mutation, it is possible that two revertant colonies with the same AraC- mutation would 
also have the same correcting mutation. However, it is unlikely that 4 revertants would all 
share genotypes if they already had unique AraC- mutations before secondary mutations 
were generated. The repetition seen here implies that the AraC- colonies selected were 
descendants of the same transformant when mutated plasmid was transformed into 
SH321 cells in the AraC- generation steps. To minimize duplication of transformants, I 
decided to separate colonies immediately after the heat-shock step in future 




The most likely explanation for the genotypes seen in these revertants is that the 
primary mutation was W104STOP, producing a completely non-functional AraC and 
leading to no growth on arabinose. The correcting mutation could be a nonsense-
suppressor on the E. coli chromosome – which would not appear in plasmid sequencing. 
Finally, R84H could have an insignificant effect on AraC function. R84H has not 
previously been characterized, but both arginine and histidine residues are basic, and 
most single substitutions do not significantly affect protein function. 
 
R62R, Q54frameshift 
This colony had a silent mutation and a frameshift mutation. The Q54frameshift 
was likely the primary mutation, and it would be expected to produce a non-functional 
AraC. A secondary correcting mutation could be a frameshift-suppressing mutation on 
the E. coli chromosome. Finally, the R62R mutation is silent and thus would not be 
predicted to affect AraC function. 
The goal of this approach was to generate single-amino acid substitutions to study 
the structure and function of AraC. Frameshifts and nonsense mutations likely appeared 
in mutagenesis screen 2 due to the stricter selection criteria for AraC- colonies. A single-
amino acid change is unlikely to completely knock down protein function in most 
proteins, including AraC. Thus, using strict selection criteria for AraC- colonies seems 







Mutagenesis Screen 3: Lenient AraC- Selection 
In mutagenesis screen 3, the AraC- colonies were sequenced instead of the AraC+ 
revertants to verify that the AraC- generation process was working before attempting to 
identify revertants. AraC- mutations needed to be single amino acid substitutions so that 
revertants could possess two complementing substitutions. For this screen, the AraC- 
selection criteria was relaxed once more. A total of six AraC- candidates were sequenced 
without progressing to the AraC+ revertant stage (Table 7). The problem of related 
descendants persisted in the screen, indicating that the issue involves the AraC- selection 
step. Remarkably, one colony was found to have a WT AraC sequence despite having 
reduced growth on min/ara/amp. On the other hand, two other colonies were able to 
partially grow on min/ara/amp despite having a frameshift mutation at residue 97; they 
are discussed below. 
 
Table 7. AraC- candidates that were sequenced in mutagenesis screen 3. 
Colony Mutations Amino Acid Changes 
11 97(TAC  TA–) 
 
Y97frameshift 
12 97(TAC  TA–) 
 
Y97frameshift 
13 Wild Type 
 
 
14 83(GGT  GCT) 
214(CTT  TTT) 





15 83(GGT  GCT) 
214(CTT  TTT) 





16 83(GGT  GCT) 
214(CTT  TTT) 









This mutation is interesting because a frameshift so early in the protein sequence 
should render a completely non-functional AraC. However, both colonies exhibited some 
growth on arabinose, although less than WT. Therefore, I postulate that some other 
mutation occurred in addition to the frameshift. One explanation would be an in-frame 
translation restart after the frameshift, producing two polypeptide fragments that could 
later combine into a functional AraC (Eustance & Schleif, 1996). However, there are 
neither possible restart codons after the frameshift nor STOP codons near residue 97 
either with or without the frameshift. With this restart model excluded, further study 
would be needed to understand colonies possessing Y97frameshift. The most likely 
explanation is that there is some complementing phenomenon occurring, but not visible 
in the coding sequence of the araC on the plasmid. There could be a mutation elsewhere 
on the plasmid or possibly on the E. coli chromosome. 
 
WT 
One colony demonstrates the risk of using lenient AraC- selection – a WT colony 
could be selected as AraC- when looking for marginally decreased growth. Alternatively, 
there may be mutations outside of the AraC coding sequence that contribute to decreased 
growth – such as a mutation in the PC promoter or a mutation on the E. coli chromosome. 
 
G83A, L214F, and K290E 
None of the three mutations found has been previously characterized. The triple 




three mutations contributed to decreased AraC function. This triple mutant, however, 
may be worthwhile to pursue in future studies. Before progressing to the stage of 
generating correcting mutations, the process for creating AraC- mutations must be 
optimized because none of the 6 AraC- candidates sequenced in mutagenesis screen 3 had 
a single amino acid substitution. 
 
Using a High Copy Number Plasmid Introduces Confounding Data 
The copy number of pBAD-GFP is several hundred plasmids per cell. A decrease 
in AraC function may not result in a proportional decrease in PBAD induction – and thus 
growth – if araC is expressed from many plasmids. A sufficient amount of partially 
active AraC could provide enough induction for a WT growth phenotype. Additionally, 
having multiple plasmids poses a problem if they are not identical. In the method used, 
AraC+ revertants were generated through random mutation in cells that contained 
hundreds of pBAD-GFP plasmids. Each copy would mutate independently, so the 
extracted plasmid DNA could be heterogeneous. Transformation and using a low copy 
number plasmid are two approaches to mitigate the problem. During transformation, 
bacterial cells are generally expected to take up a single plasmid, particularly if standard 
protocols are employed.  
The mechanism of transformation ensures that only a single plasmid will be 
present in a cell until replication is allowed to occur. Without any selective pressures, 
only a trivial number of plasmids extracted and sequenced after growth should have 
additional mutations. However, a more comprehensive solution would be to use a low 




Mutagenesis Screen 4: Using a Plasmid with Controllable Copy Number 
 The pCCN plasmids (pCCN-GFP and pCCN-mCherry) contain the PBAD 
regulatory region, but they can be maintained at controllable copy number in the presence 
of the lac repressor, supplied by pSE380. To perform screens using pCCN, pSE380 was 
transformed into competent SH321 cells. pCCN was then transformed into the resulting 
SH321-pSE380 cells, and primary amino acid substitutions were generated as described 
in the method above, without progressing to generating revertants. Before sequencing, 
plasmid DNA was digested with restriction enzymes unique to pSE380. The remaining 
pCCN was re-transformed into SH321 cells lacking pSE380, then cells were grown in 5 
mL YT/kan. Plasmid DNA was extracted, and the araC genes were sequenced. Seven 
AraC- colonies were sequenced (Table 8). 
 
Table 8. AraC- candidates that were sequenced in mutagenesis screen 4. 
Colony Mutations Amino Acid Changes 
17 
 
66(TGC  TAC) C66Y 
18 
 
114(TTT  CTT) F114L 
19 
 
114(TTT  CTT) F114L 
20 
 




114(TTT  CTT) 





33(TTT  TTTT) F33frameshift 
23 270(GGG  GG–) G270frameshift 
 
C66Y 
 Residue 66 lies buried in the β-barrel of the dimerization domain. Due to the 




plausible that removal of the cysteine may result in an improperly folded protein and thus 
an AraC- phenotype. This mutation is a possible candidate for reversion in future studies. 
 
F114L 
 Residue 114 lies near the β-barrel of the dimerization domain, but is partially 
exposed. The side chain of residue 114 may interact with other residues within the β-
barrel. This residue is a good candidate for reversion in future studies. 
 
F114L and D229N 
 F114L was described above; the single amino substitution is sufficient to produce 
an AraC- phenotype. Residue 229 lies in the DNA-binding domain of AraC and is not 
well characterized. Without further study, it is not possible to say whether F114L and 
D229N act together to produce an AraC- phenotype, whether D229N causes an AraC- 
phenotype on its own, or whether D229N produces no functional change, and the 
phenotype observed was only due to F114L. 
 
F33frameshift 
 This frameshift involved the introduction of an additional thymine in the 7-
thymine sequence corresponding to residues 33-35. This mutation would be expected to 
produce an AraC protein that has the correct amino acid sequence for residues 1-35, an 
incorrect amino acid sequence for residues 36-69, and termination after residue 69 due to 






 This frameshift was due to the deletion of a guanine at residue 270. This mutant 
likely loses its ability to bind DNA, as the final α-helix of the DNA-binding domain is 
disrupted. The mutation present here would be expected to produce the correct amino 
acid sequence for residues 1-270, an incorrect sequence for residues 270-283, and 
termination after residue 283. 
 
Refining of the Selection System 
 In mutagenesis screen 4, two frameshift mutations occurred in regions with 
repeated nucleotides (e.g. 7-thymine sequence). Frameshifts likely occur at high 
frequencies in these regions due to increased DNA polymerase slippage. Even with a 
single copy number plasmid, frameshifts may persist in the generation of AraC- 
mutations. However, the use of pCCN successfully generated two mutants with single 
amino acid substitutions. A controllable copy number plasmid appears to be the best 
construct for this genetic method. 
 To further refine the screening system by eliminating the high copy number 
pSE380 plasmid, the cell line RS321 was developed (Schleif, unpublished). RS321 cells 
contain the lacI gene and IQ promoter, allowing for control of pCCN copy number using 
only IPTG. Preliminary tests in the system demonstrated that RS321 functions as 
expected. RS321 cells containing pCCN-GFP and pCCN-mCherry grown with arabinose 
and IPTG produced significant fluorescence from GFP or mCherry. Cells grown with 
only arabinose, only IPTG, or neither did not produce visible fluorescence. Future studies 




Summary of Mutagenesis Screens (Chapter 4) 
 My proposed method of generating complementing amino acid substitutions in 
AraC establishes a foundation upon which future studies may build. The system of using 
a controllable copy number plasmid to encode araC and the lacIQ strain RS321 to 
conduct genetic screens is one that has been developed with significant thought after 
many experiments in other systems. Although pairs of complementing substitutions have 
not yet been consistently identified in AraC, the success of this genetic approach in 
studying other proteins suggests that it can be applied to AraC. The complementing 
substitutions method holds promise for answering questions about AraC where other 
approaches have failed. Once my method is completely refined, the payoff – both to 
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